New weight loss drug IBIO-600 enters first human trial
NCT ID NCT07487376
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a single dose of the experimental drug IBIO-600 in 32 overweight or obese adults. The main goal is to see if the drug is safe and tolerable, and to measure how it moves through the body. Researchers will also look at its effect on body composition. This is a first step toward possibly developing a new weight management treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- IBIO-600
- What this could lead to
- If it works, this could point toward a new treatment for weight management in people who are overweight or obese.
- What could go wrong
- This is a very early Phase 1 trial with only 32 participants, so it's primarily checking safety, not effectiveness. The drug may not lead to meaningful weight loss or could have side effects.
Why investors are watching
iBio is a very small publicly traded company, and this phase 1 trial is its first test of IBIO-600 in people. The study gives 32 overweight or obese adults a single dose to check safety and whether the drug changes body composition. For a micro-cap company, this early readout is a key signal about whether its lead drug has a future.
If it works: If IBIO-600 proves safe and shows a hint of effect on body composition, iBio could advance the drug to larger studies. That progress could raise the company's profile and support its value as a drug developer.
If it fails: Phase 1 trials often fail on safety or tolerability, and this one has only 32 participants, so results may be unclear. A poor outcome or a delay could hurt iBio's prospects, since the company has few other public assets to fall back on.
AI-written from the trial record. Speculative, and not investment advice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 32 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2026
- Expected to finish
-
May 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Aged 18 to 65 years of age * In good general health, with no significant medical history * BMI between ≥ 27.0 and ≤ 34.90 kg/m2 * History of self-reported stable body weight (defined as change of no more or less than ± 5%) within 90 days of Screening. * Willingness to refrain from any reconstructive and/or cosmetic surgery and/or non-invasive cosmetic procedure that may affect body weight during the study * Must be fully ambulatory without any chronic orthopedic diseases or reliance on crutches, walkers, or a wheelchair that may preclude normal activity. * Be a nonsmoker/nonvaper and must not have used any nicotine or synthetic type products within 1 month prior to randomization. * Must not be pregnant or breastfeeding * Woman of childbearing potential (WOCBP) or fertile man agrees to use an acceptable method of contraception from the start of Screening until study completion, or for a minimum of 9 months following the last dose of IP, whichever period is longer. Exclusion Criteria: * An underlying physical or psychological medical conditions that, in the opinion of the PI or medical designee, would make the participant unlikely to comply with the protocol or complete the study per protocol. * History or active diagnosis of diabetes (Type 1 or 2). * History of insulinoma or recurrent hypoglycemia (≥ 3 episodes in past 3 months). * History or presence of clinically significant muscle disease * History of or active cardiovascular disease including clinically significant arrhythmias, Class I-IV heart failure, coronary artery disease, thromboembolic event, or pulmonary hypertension. * Clinically significant laboratory abnormalities that would preclude participation in the study. * History of malignancy, except for non-melanoma skin cancer excised \> 2 years ago or cervical intraepithelial neoplasia successfully treated \> 5 years prior to randomization. * History or presence of any condition associated with significant immunosuppression. * History of substance abuse or dependency, or recreational IV drug use within the past 5 years (self-reported).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Overweight/obesity are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Veritus Research
RECRUITINGBayswater, Victoria, 3153, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a brazilian diet calm menopause hot flashes?
- Can a glucose monitor personalize weight loss for students?
- Mushrooms and a repurposed antidepressant: a new recipe for weight loss?
- Can a damaged kidney change how a drug works?
- Can a new injection help tackle obesity? a trial puts MWN105 to the test
- Oral pill aims to keep weight off after initial loss